Novartis has begun a placebo-controlled phase 3 trial of votoplam, a once-daily pill formerly coded PTC518, in people with early symptomatic Huntington's disease. The registration on ClinicalTrials.gov (NCT07326709, the INVEST-HD study) gives an actual study start of March 24, 2026, an estimated enrolment of 770 participants, randomisation in a 3:2 ratio to blinded votoplam or placebo, a double-blind treatment period of up to 36 months, and an estimated primary completion of April 2, 2030. The registry entry sets narrow eligibility: ambulatory adults aged 21 to 70, genetically confirmed disease with a CAG repeat length of 40 or above, a Total Functional Capacity score of 13, a Total Motor Score of 7 to 25 and a CAP100 score of 70 or above. It also excludes anyone with a history of gene therapy, cell transplantation or other experimental brain surgery for Huntington's disease, which sets this trial apart from the surgical gene therapy route being tested elsewhere. Novartis has said sites are being activated in stages, with the first two North American sites open in March 2026 and recruitment planned across more than 30 countries.

The phase 3 trial follows interim topline results, reported by PTC Therapeutics on April 28, 2026, from the long-term extension of the phase 2 PIVOT-HD study, and restated in the company's quarterly update on July 30, 2026. After 24 months of votoplam, PTC reported dose-dependent slowing of progression on the Composite Unified Huntington's Disease Rating Scale in Stage 2 participants of 52 per cent at the 10 mg dose and 28 per cent at 5 mg, measured against a propensity-weighted natural history comparison group drawn from the ENROLL-HD registry. The company reported no treatment-related increases in neurofilament light chain, a marker of nerve cell damage, with mean levels remaining below baseline at 24 months at both doses, and described potential signals of slowing in Stage 3 participants and a safety profile consistent with earlier data.

Those figures are interim and topline, and have not been peer reviewed. Everyone in the extension study is taking active drug: those who received 5 mg or 10 mg in PIVOT-HD continued on that dose, and those originally given placebo were reallocated to a dose, so the comparison is with an outside registry cohort rather than an internal placebo group. PIVOT-HD itself was a 12-month study whose primary endpoints were blood huntingtin lowering at 12 weeks and safety, not clinical progression. Percentage slowing against a matched external cohort depends on how well that cohort matches, and the HD research charity HDBuzz noted in May 2026 that 24-month huntingtin protein levels, full Stage 3 subscale data and brain MRI results were still outstanding, with the complete dataset due at a scientific meeting later in 2026.

INVEST-HD exists to answer precisely the question the extension cannot: whether the pill slows progression more than placebo in people randomly assigned to one or the other. Its primary measure is change in the cUHDRS over up to 36 months, and results are not expected until 2030. Votoplam remains investigational and is not approved for any use.